Antonini A, et al. - The 24-month safety and efficacy of levodopa-carbidopa intestinal gel (LCIG) treatment in advanced Parkinson's disease (PD) patients under routine clinical care were evaluated. By using LCIG, the authors found sustained improvements in motor fluctuations, non-motor symptoms, particularly sleep/fatigue, mood/cognition and gastrointestinal domains, as well as the quality of life in advanced PD patients over 24 months. With the established safety profile of LCIG, safety events were consistent.